Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 11 mechanisms across 30 industry trials with a known mechanism of action.

See full pipeline →

Integrin Receptor Antagonist

7 trials 2 active 2 sponsors

Janus Kinase Inhibitor

3 trials 1 active 1 sponsor

Interleukin-23 Antagonist

1 trials 1 active 1 sponsor

TNF

7 trials 3 sponsors

Aminosalicylate

5 trials 4 sponsors

Tumor Necrosis Factor Blocker

2 trials 2 sponsors

Tyrosine Kinase 2 Inhibitor

1 trials 1 sponsor

Phosphodiesterase 4 Inhibitor

1 trials 1 sponsor

Tryptophan Hydroxylase

1 trials 1 sponsor

Interleukin-13 Antagonist

1 trials 1 sponsor

Kinase Inhibitor

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

318 industry-sponsored trials across 136 sponsors

View full landscape →

Showing 13 of 13 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Bausch Health Americas, Inc.	Low Dose Budesonide	—	RECRUITING	2026-12	NCT04314375
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	RECRUITING	2027-07-09	NCT06095128
Takeda	Vedolizumab IV	—	RECRUITING	2027-10-01	NCT06581328
Eisai Korea Inc.	Filgotinib Maleate	—	RECRUITING	2027-11-30	NCT06964113
Bausch Health Americas, Inc.	High dose budesonide rectal foam	—	NOT YET RECRUITING	2029-06	NCT05976802
Rubix LS	Mirikizumab	—	NOT YET RECRUITING	2026-01-01	NCT07059130
Takeda	Vedolizumab IV	—	COMPLETED	2024-02-02	NCT04804540
Merck	Golimumab	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2016-05-25	NCT02092285
Merck	Prefilled Syringe delivery of Golimumab	—	COMPLETED	2015-10-05	NCT02155335
Otsuka Pharmaceutical Europe Ltd	—	—	COMPLETED	2015-05	NCT01481142
Takeda	MMX mesalamine/ mesalazine	—	COMPLETED	2012-12-07	NCT01124149
Pfizer	CP-690,500 5 mg	—	TERMINATED	2020-02-14	NCT03281304
Asahi Kasei Medical Co., Ltd.	—	—	TERMINATED	2012-01	NCT00947674

Showing 100 of 101 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Roche	Afimkibart	—	RECRUITING	2027-01-30	NCT06588855
Takeda	Vedolizumab IV	—	RECRUITING	2027-09-24	NCT03221036
Takeda	Vedolizumab IV	—	RECRUITING	2027-11-15	NCT06100289
Eli Lilly	Mirikizumab	—	RECRUITING	2028-04	NCT06937086
Sanofi	Duvakitug	—	RECRUITING	2028-05-09	NCT07184996
Alfasigma S.p.A.	Filgotinib	—	RECRUITING	2028-06	NCT06865417
AbbVie	Risankizumab	—	RECRUITING	2028-09	NCT06880744
Sanofi	Duvakitug	—	RECRUITING	2028-09-21	NCT07185009
Roche	Afimkibart	—	RECRUITING	2030-03-31	NCT07158242
Eli Lilly	Mirikizumab	—	RECRUITING	2030-12	NCT04844606
Takeda	Vedolizumab SC	—	RECRUITING	2032-01-26	NCT06405087
Takeda	Vedolizumab IV	—	RECRUITING	2033-02-07	NCT05442567
AbbVie	Risankizumab	—	RECRUITING	2034-07	NCT07071519
Eli Lilly	Mirikizumab IV	—	RECRUITING	2026-05	NCT05784246
Merck	IV Tulisokibart	—	ACTIVE NOT RECRUITING	2026-08-01	NCT06052059
Alfasigma S.p.A.	Filgotinib	—	ACTIVE NOT RECRUITING	2026-09	NCT02914535
Roche	Afimkibart	—	ACTIVE NOT RECRUITING	2027-01-30	NCT06589986
Pfizer	tofacitinib	—	ACTIVE NOT RECRUITING	2027-04-28	NCT04624230
AbbVie	Upadacitinib (ABT-494)	—	ACTIVE NOT RECRUITING	2027-07	NCT03006068
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	ACTIVE NOT RECRUITING	2028-08	NCT05782907
AbbVie	risankizumab	—	ACTIVE NOT RECRUITING	2028-09	NCT03398135
Pfizer	Etrasimod	—	ACTIVE NOT RECRUITING	2029-06-19	NCT03950232
Abivax S.A.	ABX464	—	ACTIVE NOT RECRUITING	2026-04	NCT05535946
Eli Lilly	Mirikizumab	—	ACTIVE NOT RECRUITING	2026-03-04	NCT03519945
Polpharma Biologics S.A.	Intravenous (IV) infusions	—	ACTIVE NOT RECRUITING	2025-09	NCT05771155
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	ACTIVE NOT RECRUITING	2025-05-30	NCT04738942
Eli Lilly	Mirikizumab	—	ACTIVE NOT RECRUITING	2024-08-09	NCT05767021
Johnson & Johnson	Guselkumab	Interleukin-23 Antagonist [EPC]	ACTIVE NOT RECRUITING	2023-09-19	NCT04033445
Abivax S.A.	ABX464	—	COMPLETED	2025-06-24	NCT05507203
Abivax S.A.	ABX464	—	COMPLETED	2025-06-24	NCT05507216
AbbVie	Adalimumab	TNF	COMPLETED	2025-04-08	NCT02632175
Bristol-Myers Squibb	RPC1063	—	COMPLETED	2024-12-19	NCT02531126
Takeda	25 mg Ontamalimab	—	COMPLETED	2023-12-13	NCT03283085
AbbVie	risankizumab IV	—	COMPLETED	2022-11-09	NCT03398148
Pfizer	Etrasimod	—	COMPLETED	2022-08-03	NCT04706793
Celltrion	CT-P13 SC (Infliximab)	—	COMPLETED	2022-07-07	NCT04205643
Arena Pharmaceuticals	Etrasimod	—	COMPLETED	2022-02-08	NCT03945188
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2021-12-13	NCT02819635
Arena Pharmaceuticals	Etrasimod	—	COMPLETED	2021-12-07	NCT03996369
Eli Lilly	Mirikizumab SC	—	COMPLETED	2021-11-03	NCT03524092
Takeda	Ontamalimab	—	COMPLETED	2021-07-01	NCT03290781
Eli Lilly	Mirikizumab	—	COMPLETED	2021-01-21	NCT03518086
AbbVie	Upadacitinib	Janus Kinase Inhibitor [EPC]	COMPLETED	2021-01-14	NCT03653026
Pfizer	CP-690,550	—	COMPLETED	2020-08-06	NCT01470612
Roche	Etrolizumab	—	COMPLETED	2020-06-23	NCT02136069
Roche	Etrozulimab	—	COMPLETED	2020-04-16	NCT02100696
Gilead	Filgotinib	—	COMPLETED	2020-03-31	NCT02914522
Bristol-Myers Squibb	RPC1063	—	COMPLETED	2020-03-27	NCT02435992
Roche	Adalimumab	TNF	COMPLETED	2020-03-02	NCT02171429
Roche	Adalimumab	TNF	COMPLETED	2020-02-19	NCT02163759
AbbVie	Adalimumab	TNF	COMPLETED	2020-02-07	NCT02065557
AbbVie	Adalimumab	TNF	COMPLETED	2019-09-05	NCT02065622
Takeda	MMX Mesalamine/Mesalazine (Low Dose)	—	COMPLETED	2018-11-28	NCT02093663
Dr. Falk Pharma GmbH	LT-02	—	COMPLETED	2018-10-05	NCT02280629
Ferring Pharmaceuticals	Mesalamine	Aminosalicylate [EPC]	COMPLETED	2018-09-19	NCT02522780
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2018-02-27	NCT02039505
Ferring Pharmaceuticals	Mesalamine	Aminosalicylate [EPC]	COMPLETED	2018-02-06	NCT02522767
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2017-10-31	NCT00790933
Ferring Pharmaceuticals	Mesalazine Enema	—	COMPLETED	2017-01-05	NCT02368717
Pfizer	CP690,550	—	COMPLETED	2016-05-27	NCT01458574
Tillotts Pharma AG	TP05	—	COMPLETED	2016-05	NCT01903252
Pfizer	tofacitinib	—	COMPLETED	2015-05	NCT01465763
Pfizer	tofacitinib	—	COMPLETED	2015-05	NCT01458951
AbbVie (prior sponsor, Abbott)	Adalimumab	TNF	COMPLETED	2015-04	NCT01550965
Dr. Falk Pharma GmbH	Mesalazine - TID 1000 mg	—	COMPLETED	2015-03	NCT01745770
Tanabe Pharma Corporation	TA-650	—	COMPLETED	2014-09	NCT01585155
Xian-Janssen Pharmaceutical Ltd.	Infliximab	Tumor Necrosis Factor Blocker [EPC]	COMPLETED	2014-03	NCT01551290
Bausch Health Americas, Inc.	Budesonide MMX®	—	COMPLETED	2013-10-02	NCT01532648
Shield Therapeutics	ST10-021	—	COMPLETED	2013-10	NCT01340872
Tillotts Pharma AG	Asacol®	—	COMPLETED	2013-01	NCT01257399
Nordisk Rebalance A/S	—	—	COMPLETED	2012-09	NCT01193894
Tillotts Pharma AG	Asacol®	—	COMPLETED	2012-08	NCT01257386
Millennium Pharmaceuticals, Inc.	vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2011-12	NCT00783718
Tillotts Pharma AG	Mesalamin	—	COMPLETED	2011-07	NCT01059344
Bausch Health Americas, Inc.	Budesonide MMX 6 mg Tablet	—	COMPLETED	2011-05	NCT00801723
AbbVie (prior sponsor, Abbott)	adalimumab	TNF	COMPLETED	2011-05	NCT00853099
Warner Chilcott	Asacol 400 mg	—	COMPLETED	2011-03	NCT00713310
Ferring Pharmaceuticals	Mesalazine slow-release granules	—	COMPLETED	2010-06	NCT00737789
Bausch Health Americas, Inc.	budesonide-MMX® 6 mg	—	COMPLETED	2010-05	NCT00679432
Bausch Health Americas, Inc.	Budesonide MMX® 6 mg	—	COMPLETED	2010-02	NCT00679380
Vifor Pharma	Ferric carboxymaltose	—	COMPLETED	2009-12	NCT00810030
EMET Pharmaceuticals, LLC	Mesalamine	Aminosalicylate [EPC]	COMPLETED	2009-06	NCT01045018
Alvotech Swiss AG	AVT16	—	TERMINATED	2025-11-25	NCT06570772
Bristol-Myers Squibb	Ozanimod	—	TERMINATED	2025-03-07	NCT05644665
InDex Pharmaceuticals	Cobitolimod 250 mg	—	TERMINATED	2023-12-20	NCT04985968
Galapagos NV	Filgotinib	—	TERMINATED	2023-10-09	NCT05479058
Roche	Etrolizumab	—	TERMINATED	2023-10-05	NCT02118584
Theravance Biopharma	TD-1473 Dose A	—	TERMINATED	2021-10-27	NCT03920254
Theravance Biopharma	TD-1473 Dose A	—	TERMINATED	2021-10-20	NCT03758443
Takeda	Ontamalimab	—	TERMINATED	2020-07-22	NCT03259334
Takeda	Ontamalimab	—	TERMINATED	2020-07-15	NCT03259308
Prometheus Laboratories	LT-02	—	TERMINATED	2019-03	NCT02849951
Dr. Falk Pharma GmbH	LT-02	—	TERMINATED	2016-11-11	NCT02142725
Gilead	Andecaliximab	—	TERMINATED	2016-09	NCT02520284
Hutchison Medipharma Limited	HMPL-004	—	TERMINATED	2014-10	NCT01882764
Hutchison Medipharma Limited	HMPL-004 1800 mg/day	—	TERMINATED	2014-10	NCT01805791
sigma-tau i.f.r. S.p.A.	Propionyl-L-Carnitine	—	TERMINATED	2013-10	NCT01567956
sigma-tau i.f.r. S.p.A.	Propionyl-L-Carnitine	—	TERMINATED	2013-10	NCT01538251
Warner Chilcott	Asacol 400 mg	—	TERMINATED	2011-03	NCT01004185
AbbVie	Mesalamine	Aminosalicylate [EPC]	WITHDRAWN	2026-07-19	NCT05316220

Showing 100 of 137 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Spyre Therapeutics, Inc.	SPY001	—	RECRUITING	2026-06	NCT07012395
Roche	Vixarelimab	—	RECRUITING	2026-06-09	NCT06693908
InventisBio Co., Ltd	D-2570	—	RECRUITING	2026-07-30	NCT07035041
Accro Bioscience (Suzhou) Limited	AC-101	—	RECRUITING	2026-09-30	NCT07083193
Shandong Suncadia Medicine Co., Ltd.	HRS-7085	—	RECRUITING	2026-12	NCT07229950
Sanofi	SAR442970	—	RECRUITING	2026-12-17	NCT06975722
Gilead	Tilpisertib Fosmecarbil	—	RECRUITING	2027-01	NCT06029972
Biocad	anti-TL1A monoclonal antibody, low dose	—	RECRUITING	2027-01	NCT07080034
Mirador Therapeutics, Inc.	MT-501	—	RECRUITING	2027-04-30	NCT07113522
Eli Lilly	LY4268989	—	RECRUITING	2027-05	NCT07186101
Guangdong Hengrui Pharmaceutical Co., Ltd	SHR-1139 intravenous injection.	—	RECRUITING	2027-08	NCT07232576
InSilico Medicine Hong Kong Limited	ISM5411 tablets	—	RECRUITING	2027-08-15	NCT07265570
Roche	RO7837195	—	RECRUITING	2027-08-25	NCT06979336
Haisco Pharmaceutical Group Co., Ltd.	HSK47388	—	RECRUITING	2027-10-15	NCT07335055
Merck	MK-8690	—	RECRUITING	2027-10-28	NCT07463183
Eli Lilly	Eltrekibart	—	RECRUITING	2027-12	NCT06598943
Xencor, Inc.	XmAb942	—	RECRUITING	2028-04	NCT06619990
Mage Biologics	MB-001	—	RECRUITING	2028-07	NCT07374471
Pfizer	Etrasimod	—	RECRUITING	2029-06-16	NCT05287126
Takeda	Zasocitinib	—	RECRUITING	2029-12-30	NCT06764615
Eli Lilly	LY4268989	—	RECRUITING	2030-06	NCT07415044
Odyssey Therapeutics	OD-07656	—	RECRUITING	2026-04	NCT06850727
Takeda	TAK-279	—	ACTIVE NOT RECRUITING	2026-09-30	NCT06254950
Ganzhou Hemay Pharmaceutical Co., Ltd	Hemay005 tablets	—	ACTIVE NOT RECRUITING	2026-12-30	NCT05486104
AbbVie	Lutikizumab	—	ACTIVE NOT RECRUITING	2027-09	NCT06257875
Abivax S.A.	ABX464	—	ACTIVE NOT RECRUITING	2028-03	NCT05177835
AltruBio Inc.	ALTB-268	—	ACTIVE NOT RECRUITING	2026-03-05	NCT06109441
Gilead	emvistegrast	—	ACTIVE NOT RECRUITING	2026-03-04	NCT06290934
Boehringer Ingelheim	BI 3032950 intravenous (Part A)	—	ACTIVE NOT RECRUITING	2026-01-14	NCT06636656
AnaptysBio, Inc.	Rosnilimab	—	ACTIVE NOT RECRUITING	2026-01	NCT06127043
Palatin Technologies, Inc	PL8177	—	ACTIVE NOT RECRUITING	2025-02-10	NCT05466890
Nanjing Immunophage Biotech Co., Ltd	IPG11406	—	NOT YET RECRUITING	2028-12-01	NCT07535489
Athos Therapeutics Inc	ATH-063	—	NOT YET RECRUITING	2028-12-14	NCT07513181
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	627	—	NOT YET RECRUITING	2029-02-28	NCT07507513
Jina Pharmaceuticals Inc.	Tacrolimus Lipid Suspension for enema	—	NOT YET RECRUITING	2025-12	NCT06867042
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2025-04-03	NCT03196427
BioGaia Pharma AB	BGP-014	—	COMPLETED	2024-12-31	NCT05118919
AbbVie	ABBV-668	—	COMPLETED	2024-12-23	NCT05570006
Zydus Lifesciences Limited	Arm1	—	COMPLETED	2024-11-22	NCT06398808
Shanghai Pharmaceuticals Holding Co., Ltd	SPH3127 Tablets with Dose A	—	COMPLETED	2024-09-13	NCT05770609
Bausch Health Americas, Inc.	Low Dose MT-1303	—	COMPLETED	2024-09-03	NCT04857112
Innovent Biologics (Suzhou) Co. Ltd.	Period 2 IBI112 dose 3	—	COMPLETED	2024-06-21	NCT05377580
Pfizer	Etrasimod	—	COMPLETED	2024-06-19	NCT04607837
OSE Immunotherapeutics	OSE-127	—	COMPLETED	2024-04-30	NCT04882007
Pfizer	Etrasimod	—	COMPLETED	2023-10-06	NCT05061446
Bristol-Myers Squibb	Deucravacitinib	Tyrosine Kinase 2 Inhibitor [EPC]	COMPLETED	2023-08-29	NCT04877990
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Tulisokibart	—	COMPLETED	2023-06-06	NCT04996797
Eli Lilly	Mirikizumab	—	COMPLETED	2023-03-15	NCT04004611
Abivax S.A.	ABX464	—	COMPLETED	2023-02-23	NCT04023396
Protagonist Therapeutics, Inc.	PN-943	—	COMPLETED	2023-02-16	NCT04504383
Oncostellae S.L	OST-122	—	COMPLETED	2022-12-27	NCT04353791
Roche	Induction- PF-06480605 50 mg SC Q4W	—	COMPLETED	2022-10-25	NCT04090411
Abivax S.A.	ABX464	—	COMPLETED	2022-07-12	NCT03368118
Applied Molecular Transport	AMT-101 (oral)	—	COMPLETED	2022-06-01	NCT05372939
Bridge Biotherapeutics, Inc.	BBT-401-1S or Placebo	—	COMPLETED	2022-05-17	NCT04596293
Connect Biopharm LLC	Double-Blind 0.2mg CBP-307	—	COMPLETED	2022-02-23	NCT04700449
ParaTech A/S	Trichuris suis ova	—	COMPLETED	2022-01-10	NCT03565939
Roche	UTTR1147A	—	COMPLETED	2021-12-15	NCT03558152
Bristol-Myers Squibb	BMS-986165	—	COMPLETED	2021-06-13	NCT03934216
Palobiofarma SL	PBF-677	—	COMPLETED	2021-05-27	NCT03773952
Galapagos NV	GLPG3970	—	COMPLETED	2021-05-17	NCT04577794
Pfizer	PF-06700841	—	COMPLETED	2021-05-10	NCT02958865
AbbVie	Ravagalimab 600 mg	—	COMPLETED	2021-04-05	NCT03695185
Abivax S.A.	ABX464 100 mg	—	COMPLETED	2021-04-01	NCT03760003
I-Mab Biopharma HongKong Limited	TJ301 300mg	—	COMPLETED	2020-12-21	NCT03235752
NImmune Biopharma	BT-11 (440 mg)	—	COMPLETED	2020-12-10	NCT03861143
Reistone Biopharma Company Limited	SHR0302	—	COMPLETED	2020-11-30	NCT03675477
Takeda	Vedolizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2020-03-31	NCT03138655
InDex Pharmaceuticals	cobitolimod	—	COMPLETED	2019-08-30	NCT03178669
EA Pharma Co., Ltd.	E6007	—	COMPLETED	2019-04-17	NCT03018054
Arena Pharmaceuticals	Etrasimod	—	COMPLETED	2018-11-01	NCT02536404
Kyowa Kirin, Inc.	KHK4083	—	COMPLETED	2018-09	NCT02647866
Abivax S.A.	ABX464	—	COMPLETED	2018-07-25	NCT03093259
Arena Pharmaceuticals	Etrasimod	—	COMPLETED	2018-02-14	NCT02447302
Eli Lilly	Mirikizumab	—	COMPLETED	2017-12-19	NCT02589665
Takeda	75mg SHP647 (PF-00547659)	—	COMPLETED	2017-12-13	NCT01771809
Amgen	Apremilast	Phosphodiesterase 4 Inhibitor [EPC]	COMPLETED	2017-09-25	NCT02289417
Topivert Pharma Ltd	TOP1288	—	COMPLETED	2017-06-28	NCT02888379
Qu Biologics Inc.	QBECO SSI	—	COMPLETED	2016-12	NCT02426372
Roche	Etrolizumab	—	COMPLETED	2016-08-07	NCT01461317
Galapagos NV	GLPG1205	—	COMPLETED	2015-09	NCT02337608
AstraZeneca	MEDI7183 low dose	—	COMPLETED	2015-08-11	NCT01959165
Amgen	Abrilumab	—	COMPLETED	2015-07-13	NCT01694485
Bristol-Myers Squibb	Ozanimod	—	COMPLETED	2015-03-10	NCT01647516
Vascular Biogenics Ltd. operating as VBL Therapeutics	VB-201 160mg	—	COMPLETED	2014-11	NCT01839214
PurGenesis Technologies Inc.	PUR 0110 Rectal Enema 250 mg	—	COMPLETED	2014-10-01	NCT01149707
Takeda	PF-00547659 SC Injection	—	COMPLETED	2014-09-22	NCT01620255
GW Research Ltd	GWP42003	—	COMPLETED	2014-08-05	NCT01562314
Telsar Pharma Inc.	ASP3291	—	COMPLETED	2014-04	NCT01612039
Galapagos NV	GLPG0974	—	COMPLETED	2014-04	NCT01829321
Lexicon Pharmaceuticals	Telotristat Etiprate	Tryptophan Hydroxylase	COMPLETED	2013-09-03	NCT01456052
BioLineRx, Ltd.	BL-7040	—	COMPLETED	2013-05	NCT01506362
AstraZeneca	tralokinumab	Interleukin-13 Antagonist [EPC]	COMPLETED	2013-03	NCT01482884
Roche	rhuMAb Beta7	—	COMPLETED	2012-09	NCT01336465
Cosmo Technologies Ltd	—	—	COMPLETED	2012-07	NCT01520324
Novartis	AEB071	—	COMPLETED	2012-04	NCT00572585
Sigmoid Pharma	CyCol™	—	COMPLETED	2011-08	NCT01033305
Pfizer	CP- 690 550	—	COMPLETED	2010-09	NCT00787202
Palau Pharma S.L.U.	Dersalazine sodium	—	COMPLETED	2010-06	NCT00808977
Biogen	BG9418 (Interferon beta-1a)	—	COMPLETED	2010-03	NCT00616434

Showing 67 of 67 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Rise Therapeutics LLC	R-3750	—	RECRUITING	2026-07	NCT05666960
Jiangsu Carephar Pharmaceutical Co., Ltd.	H021	—	RECRUITING	2025-02-27	NCT06627556
AltruBio Inc.	ALTB-268	—	ACTIVE NOT RECRUITING	2026-09-26	NCT07350577
LyncBio Therapeutics Co., Ltd.	LYNC-101	—	NOT YET RECRUITING	2027-03-19	NCT07505030
Liveome Inc.	LIV001	—	NOT YET RECRUITING	2026-01-17	NCT06749795
Microbiotica Ltd	MB310	—	COMPLETED	2026-01-08	NCT06582264
NIBEC Co., Ltd.	NP-201 acetate injection (Part A)	—	COMPLETED	2025-07-18	NCT06681389
Palisade Bio	PALI-2108	—	COMPLETED	2025-07-07	NCT06663605
Mage Biologics	MB-001	—	COMPLETED	2025-07-04	NCT06363383
Odyssey Therapeutics	OD-07656	—	COMPLETED	2024-11-25	NCT06206811
Sorriso Pharmaceuticals, Inc.	SOR102	—	COMPLETED	2024-10-16	NCT06080048
Liveome Inc.	LIV001	—	COMPLETED	2024-03-05	NCT05975047
Athos Therapeutics Inc	ATH-063	—	COMPLETED	2024-02-08	NCT05807971
Merck	MK-6194	—	COMPLETED	2024-01-08	NCT04924114
Adiso Therapeutics	BT051 200 mg	—	COMPLETED	2022-11-30	NCT05084261
AbbVie	Risankizumab	—	COMPLETED	2022-10-14	NCT04254783
Innovo Therapeutics, Inc.	INV-101	—	COMPLETED	2022-07-16	NCT05844592
Landos Biopharma Inc.	NX-13 250mg IR	—	COMPLETED	2022-06-17	NCT04862741
Akeso	AK101 IV	—	COMPLETED	2022-05-17	NCT06281704
Landos Biopharma Inc.	NX-13 250 mg	—	COMPLETED	2020-10-21	NCT04458805
LG Chem	Film-coated tablet	—	COMPLETED	2020-10-01	NCT04360343
Applied Molecular Transport	AMT-101	—	COMPLETED	2020-04-30	NCT04224857
Fresenius Kabi SwissBioSim GmbH	40 mg MSB11022	—	COMPLETED	2020-03-17	NCT04018599
Roche	UTTR1147A	—	COMPLETED	2020-02-19	NCT02749630
GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	GB004	—	COMPLETED	2019-12-17	NCT03860896
Provention Bio, Inc.	PRV-300	—	COMPLETED	2019-03-01	NCT03849599
Celltrion	CT-P13	—	COMPLETED	2019-02-04	NCT02883452
Bridge Biotherapeutics, Inc.	BBT-401-1S, Single dose	—	COMPLETED	2018-09-26	NCT03482648
Theravance Biopharma	TD-1473	—	COMPLETED	2018-03-29	NCT02818686
Kyowa Kirin Co., Ltd.	KHK4083	—	COMPLETED	2017-12-26	NCT02985593
Seres Therapeutics, Inc.	SER-287	—	COMPLETED	2017-12-06	NCT02618187
Theravance Biopharma	TD-3504	—	COMPLETED	2017-11-08	NCT03103412
VHsquared Ltd.	V565	—	COMPLETED	2017-10-24	NCT03705117
Bristol-Myers Squibb	BMS-986166	—	COMPLETED	2017-08-10	NCT03038711
Bausch Health Americas, Inc.	Apriso 0.375G ER CAP	—	COMPLETED	2017-06-23	NCT03327558
Topivert Pharma Ltd	TOP1288	—	COMPLETED	2017-06-02	NCT03071081
Topivert Pharma Ltd	TOP1288	—	COMPLETED	2016-07	NCT02463045
Lycera Corp.	LYC-30937	—	COMPLETED	2016-06	NCT02818543
Gilead	Andecaliximab	—	COMPLETED	2015-01-05	NCT01831427
Gilead	GS-5745 SC	—	COMPLETED	2014-10	NCT02209987
Amgen	AMG 181	—	COMPLETED	2014-04	NCT01290042
Takeda	lumbar puncture	—	COMPLETED	2014-03-31	NCT01387594
Avaxia Biologics, Incorporated	AVX 470	—	COMPLETED	2013-12	NCT01759056
Tillotts Pharma AG	TP05	—	COMPLETED	2013-11	NCT02306798
Takeda	MMX Mesalamine	—	COMPLETED	2013-06-27	NCT01130844
Tillotts Pharma AG	TP05 Coating D	—	COMPLETED	2013-02	NCT02306785
Tillotts Pharma AG	TP05 Coating A	—	COMPLETED	2012-02	NCT02306772
IBD Column Therapies International AB	—	—	COMPLETED	2011-10	NCT01097590
Roche	rhuMAb Beta7	—	COMPLETED	2011-09	NCT00694980
Telsar Pharma Inc.	ASP3291	—	COMPLETED	2011-08	NCT01320332
Altheus Therapeutics, Inc.	mesalamine	Aminosalicylate [EPC]	COMPLETED	2010-09	NCT01020708
PurGenesis Technologies Inc.	PUR 0110 Rectal Enema or Placebo Enema	—	COMPLETED	2009-08	NCT01149694
Vial Australia Pty Ltd	BB-TL1A-VIAL-HLE	—	TERMINATED	2025-12-23	NCT07029971
Pfizer	PF-07054894	—	TERMINATED	2025-11-11	NCT05549323
Direct Biologics, LLC	ExoFlo	—	TERMINATED	2024-12-01	NCT05176366
Johnson & Johnson	Ustekinumab IV Infusion	—	TERMINATED	2021-11-22	NCT03358706
Avalo Therapeutics, Inc.	MDGN-002	—	TERMINATED	2021-09-14	NCT03169894
Bridge Biotherapeutics, Inc.	BBT-401-1S	—	TERMINATED	2021-08-04	NCT04478825
Roche	RO7049665	—	TERMINATED	2021-07-22	NCT03943550
Assembly Biosciences	ABI-M201	—	TERMINATED	2021-01-20	NCT03923478
Aptevo Therapeutics	APVO210	—	TERMINATED	2020-06-30	NCT03768219
Roche	Etrolizumab	—	TERMINATED	2019-12-02	NCT03478956
Nutrition Science Partners Limited	HMPL004-6599	—	TERMINATED	2018-11-19	NCT03597971
Bristol-Myers Squibb	BMS-986184	—	TERMINATED	2017-09-27	NCT02864264
Amgen	Amg 181	—	TERMINATED	2013-01	NCT01164904
Ferring Pharmaceuticals	Microbiota suspension	—	WITHDRAWN	2026-01-15	NCT06260267
Human Genome Sciences Inc.	HGS1025	—	WITHDRAWN	2012-12	NCT01434576

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Ulcerative Colitis

TNF-alpha (20)

Novel Drugs by Company (New molecular entities)

Johnson & Johnson 3 drugs

Amgen 3 drugs

ALVOTECH USA INC 2 drugs

Viatris 2 drugs

Fresenius Kabi 2 drugs

Pfizer 2 drugs

CELLTRION INC 1 drug

SAMSUNG BIOEPIS CO LTD 1 drug

AbbVie 1 drug

Takeda 1 drug

+8 more companies

Reformulations (14 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

SAMSUNG BIOEPIS CO LTD

T5 2019

RENFLEXIS

SAMSUNG BIOEPIS CO LTD

T5 2017